Cargando…
Guillain-Barré Syndrome following Treatment with Sunitinib Malate
Sunitinib malate (Sutent, SU011248) is an oral multitargeted tyrosine kinase inhibitor (TKI) used for the treatment of metastatic renal cell carcinoma and imatinib (Gleevec)—resistant gastrointestinal stromal tumor (GIST) with few reported side effects including asthenia, myelosuppression, diarrhea,...
Autores principales: | Kanaan, Ziad, Kulairi, Zain, Titianu, Mirela, Saha, Sandip, Kumar, Sarwan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074976/ https://www.ncbi.nlm.nih.gov/pubmed/25018885 http://dx.doi.org/10.1155/2014/712040 |
Ejemplares similares
-
Guillain-Barre syndrome induced by pembrolizumab and sunitinib: A case report
por: Han, Chen, et al.
Publicado: (2020) -
Bilateral Facial Spasm Following Guillain–Barré Syndrome
por: Guduru, Zain, et al.
Publicado: (2018) -
A Rare Case of Fusobacterium Necrophorum Liver Abscesses
por: Hannoodi, Faris, et al.
Publicado: (2017) -
Clinical Outcome of Guillain-Barré Syndrome in 108 Children
por: Sen, Sandip, et al.
Publicado: (2021) -
Guillain–Barre Syndrome following Tuberculosis: A Rare Association
por: Lakhotia, Akshay Navalkishor, et al.
Publicado: (2017)